ClinicalTrials.gg
CompletedNCT04846673OPTIMUMUpdated Apr 3, 2025

Pregabalin and Alpha-lipoic Acid Combination Versus Each Monotherapy in Patients With Diabetic Peripheral Neuropathy

A Phase 4 interventional study of Pregabalin 150mg + Alpha-lipoic acid 480mg and Pregabalin 150mg in Diabetic Peripheral Neuropathy, sponsored by Yuhan Corporation. Completed at 14 sites in Korea, Republic of. Open to participants aged 19 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-04-03.

Sponsored by Yuhan Corporation · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
151
Allocation
Randomized
Ages
19 Years to 75 Years
Sex
All
01

Study summary

This study is a randomized, parallel, open-label, multicenter, phase IV clinical trial to assess the efficacy and safety of pregabalin and alpha-lipoic acid combination compared with each monotherapy in patients with diabetic peripheral neuropathy for 12 weeks.

02

Conditions studied

  • Diabetic Peripheral Neuropathy
03

In context

Lead sponsor

Yuhan Corporation is the lead sponsor of 110 studies on the registry; 8 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • aged 19 to 75
  • type 2 diabetes mellitus with (Hemoglobin A1c) ≤ 10 %
  • peripheral (eg. hands, feet) neuropathic pain (eg. abnormal sensations, numbness, pain, etc.) within 3 months (12 weeks)
  • diagnosed with diabetic peripheral neuropathy (DPN)
  • VAS pain score ≥ 40 mm
  • written

Exclusion criteria

Exclusion Criteria:

  • brittle diabetes mellitus
  • (Alanine Transaminase), AST (Aspartate Transaminase), CPK (Creatine Phosphokinase) level ≥ 3 times the (UNL) or active liver disease
  • severe renal impairment ( (estimated glomerular filtration rate) \< 60 mL/min/ 1.73m2)
  • treated with antiepileptic drugs within 1 week at randomization
  • other nervous system or neuropathic disorders that may affect pain evaluation
  • oral drug administration is not possible, or hypersensitive or allergic to pregabalin, r-thioctic acid tromethamine, thioctic acid, and other
  • pregnant, lactating, or
  • alcoholics, drug abusers, and patients who are difficult to participate in clinical trials due to psychological and emotional problems
  • have participated in other clinical trials within 30 days at screening
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
151 participants (actual)

Study arms

  • Experimental
    Pregabalin and alpha-lipoic acid combination therapy

    Alpha-lipoic acid 480 mg/tablet once daily before breakfast and Pregabalin 150 mg/tablet once daily before bedtime will be administrated for 12 weeks.

    Drug: Pregabalin 150mg + Alpha-lipoic acid 480mg

  • Experimental
    Pregabalin monotherapy

    Pregabalin 150 mg/tablet once daily before bedtime will be administrated for 12 weeks.

    Drug: Pregabalin 150mg

  • Active comparator
    Alpha-lipoic acid monotherapy

    Alpha-lipoic acid 480 mg/tablet once daily before breakfast will be administrated for 12 weeks.

    Drug: Alpha-Lipoic Acid 480mg

Interventions

06

What researchers measure

Primary outcomes

  1. visual analogue scale (VAS)

    Time frame: 12 weeks

Secondary outcomes

  1. visual analogue scale (VAS)

    Time frame: 6 weeks

  2. visual analogue scale (VAS) reduction rate of more than 30%

    Time frame: 6 weeks, 12 weeks

  3. visual analogue scale (VAS) reduction rate of more than 50%

    Time frame: 6 weeks, 12 weeks

  4. brief pain inventory Korean version, BPI-K

    Time frame: 6 weeks, 12 weeks

  5. total symptom score, TSS

    Time frame: 6 weeks, 12 weeks

  6. pain detect questionnaire, PD-Q

    Time frame: 6 weeks, 12 weeks

  7. 3 level version of Euro-Qol-5 dimensions, EQ-5D-3L

    Time frame: 6 weeks, 12 weeks

07

Study locations

14 sites
  • Pusan National University Hospital
    Busan, Korea, Republic of
  • Chosun University Hospital, School of Medicine, Chosun University
    Gwangju, Korea, Republic of
  • Dongtan Sacred Heart Hospital, Hallym University College of Medicine
    Gyeonggi-do, Korea, Republic of
  • Seoul National University Bundang Hospital
    Gyeonggi-do, Korea, Republic of
  • The Catholic University of Korea, Incheon ST. Mary's Hospital
    Incheon, Korea, Republic of
  • Jeju National University College of Medicine
    Jeju, Korea, Republic of
  • Jeonbuk National University Hospital
    Jeollabuk-do, Korea, Republic of
  • Asan Medical Center, University of Ulsan College of Medicine
    Seoul, Korea, Republic of
  • Inje University Sanggye Paik Hospital
    Seoul, Korea, Republic of
  • Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine
    Seoul, Korea, Republic of
  • Korea University Guro Hospital
    Seoul, Korea, Republic of
  • Seoul St.Mary's Hospital, The Catholic University of Korea
    Seoul, Korea, Republic of
  • Yeouido St. Mary's Hospital, The Catholic University of Korea
    Seoul, Korea, Republic of
  • Ulsan University Hospital, College of Medicine University of Ulsan
    Ulsan, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2021 to primary completion in Nov 2022, 18 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 13, 2021
First posted
Apr 15, 2021
StartActual
May 14, 2021
Primary completionActual
Nov 30, 2022
CompletionActual
Nov 30, 2022
Last update
Apr 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04846673
Lead sponsor
Yuhan Corporation
Responsible party
Sponsor
First posted
Apr 15, 2021
Start date
May 14, 2021
Primary completion
Nov 30, 2022
Completion
Nov 30, 2022
Last update
Apr 3, 2025

Study contacts

Jongchul Won
principal investigator · Inje University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pregabalin

Start the discussion